Assessment of relation between JAK2 gene and thrombosis in myeloproliferative neoplasms
Turkish Journal of Internal Medicine · 2022
DOI: 10.46310/tjim.1055305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Internal Medicine, 2022. Verfasst von Selda KAHRAMAN und 1 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Gefördert von: destekleyen kurum bulunmamaktadır.
Abstract (Originalsprache)
Background
Thrombotic complications are the most considerable etiology causing morbidity and mortality in patients with philadelphia (Ph) negative myeloproliferative neoplasms (MPN). There are many studies evaluating the association of JAK2 mutation and risk of thrombosis in MPN with inconclusive results. We also investigated the relation between JAK2 mutation in all Ph negative MPN and thrombosis. Material and Methods Thrombotic events and demographic features of 177 patients with Ph negative MPN were evaluated retrospectively.
Results
JAK2 V617 F mutation was detected in 57% of patients with essential thrombocythemia (ET), %90.3 of pateints with polycythemia vera (PV), 100% of pateints with primary myelofibrosis (PMF). Thrombotic complications occured more frequently with JAK2 mutation in all MPN patients than without (p=0.014). In JAK 2 mutation positive groups, the median age, thrombosis risk scores and leucocyte values are higher, splenomegaly and arterial and/or venous thrombosis are detected more frequently (p
Förderung
- destekleyen kurum bulunmamaktadır
Zitieren
APA
KAHRAMAN, S., & DEMİRKAN, F. (2022). Assessment of relation between JAK2 gene and thrombosis in myeloproliferative neoplasms. Turkish Journal of Internal Medicine. https://doi.org/10.46310/tjim.1055305
Vancouver
KAHRAMAN S, DEMİRKAN F. Assessment of relation between JAK2 gene and thrombosis in myeloproliferative neoplasms. Turkish Journal of Internal Medicine. 2022. doi:10.46310/tjim.1055305
BibTeX
@article{KAHRAMAN2022,
author = {KAHRAMAN, Selda and DEMİRKAN, Fatih},
title = {Assessment of relation between JAK2 gene and thrombosis in myeloproliferative neoplasms},
journal = {Turkish Journal of Internal Medicine},
year = {2022},
doi = {10.46310/tjim.1055305}
}
EUVIMED